Form 4: ALNY CFO Poulton's Future Stock Transactions

Alnylam Pharmaceuticals' CFO, Jeffrey V. Poulton, disclosed future stock acquisitions from performance-based vesting and subsequent sales for tax obligations under a pre-arranged plan.

Summary

• Jeffrey V. Poulton, EVP, Chief Financial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported future transactions under a Rule 10b5-1 plan.
• On August 15, 2025, Poulton is scheduled to acquire 4,644 shares of common stock at $0.0 price upon the vesting of a performance-based stock unit (PSU).
• This vesting is contingent on the achievement of a clinical milestone, as determined by the Issuer's People, Culture and Compensation Committee.
• Following this, on August 18, 2025, Poulton is scheduled to sell a total of 2,274 shares of common stock.
• These sales are mandatory "sell-to-cover" transactions to satisfy minimum statutory tax withholding obligations related to the vesting and settlement of restricted stock units (RSUs) granted on March 1, 2024.
• The sales occurred at weighted average prices ranging from $447.98 to $455.82 per share.
• After these transactions, Poulton's direct beneficial ownership will be 50,121 shares, with an additional 57 shares held indirectly in a managed 401(k) account.

Sentiment

Score: 6

Explanation: The filing indicates routine insider transactions under a 10b5-1 plan, which are generally neutral. However, the vesting of performance-based units due to a clinical milestone achievement is a positive indicator of company progress, slightly elevating the sentiment.

Positives

• Vesting of 4,644 performance-based stock units indicates the achievement of a clinical milestone, reflecting progress in the company's pipeline.
• The transactions are part of a pre-arranged Rule 10b5-1 plan, demonstrating structured and compliant insider trading.

Negatives

• The sale of 2,274 shares, although for tax purposes, reduces the direct beneficial ownership of a key executive.

Future Outlook

The vesting of performance-based stock units tied to a clinical milestone suggests positive progress in the company's drug development pipeline, which could imply a favorable future outlook for specific programs.

Industry Context

The achievement of a clinical milestone is a significant event in the biotechnology and pharmaceutical industry, as it de-risks development programs and can lead to future commercialization, potentially enhancing the company's competitive position.

Corporate Governance

Stakeholder Impact

• Shareholders: The vesting of performance-based units tied to a clinical milestone could be viewed positively as it indicates progress in the company's pipeline, potentially increasing long-term shareholder value. The sell-to-cover transactions are routine and expected for tax purposes.
• Employees: The vesting of equity awards is a standard part of employee compensation, reinforcing retention and performance incentives.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled insider transactions, including the vesting of performance-based equity and subsequent sales to cover tax obligations. While the vesting indicates the achievement of a clinical milestone, which is positive, the overall filing does not provide new material information that would warrant a change in investment recommendation. It confirms ongoing executive compensation practices and progress on pre-defined goals, suggesting a stable operational environment rather than a catalyst for significant price movement.

Keywords

Alnylam Pharmaceuticals, ALNY, Jeffrey V. Poulton, CFO, SEC Form 4, Insider Trading, Stock Vesting, Performance Stock Units, Restricted Stock Units, Tax Withholding, 10b5-1 Plan, Biotechnology, Pharmaceuticals, Clinical Milestone